AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6948488 — intervention group
Group type: COMPARATOR
Intervention: Occlusal treatment including splints, grinding on natural teeth, and occlusal correction of complete dentures.
Number of subjects: 33
Study 30557792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab with or without paclitaxel
Number of subjects: 989
Study 30557792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 989
Study 28679342 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laser disc decompression (PLDD)
Number of subjects: 0
Study 28679342 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (microdiscectomy)
Number of subjects: 0
Study 25381096 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with preventive swallowing rehabilitation
Number of subjects: 22
Study 25381096 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic voice analysis
Number of subjects: 22
Study 25381096 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective vocal function (VHI score)
Number of subjects: 22
Study 24400639 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal A501D IOL
Number of subjects: 62
Study 24400639 — intervention group
Group type: COMPARATOR
Intervention: Corneal J501D IOL
Number of subjects: 62
Study 21955098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 158
Study 21955098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 158
Study 21955098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 21955098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (both doses)
Number of subjects: 158
Study 19597387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based adjuvant chemotherapy
Number of subjects: 0
Study 19597387 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized adjuvant chemotherapy (discussed conceptually)
Number of subjects: 0
Study 17990228 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine-pyrimethamine
Number of subjects: 559
Study 17990228 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 559
Study 17990228 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 559
Study 15887503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector (0.1% fluoride)
Number of subjects: 19
Study 15887503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec (1% chlorhexidine and 1% thymol)
Number of subjects: 19
Study 15887503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 15887503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector and Cervitec
Number of subjects: 19
Study 12034583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22071
Study 9579121 — intervention group
Group type: EXPERIMENTAL
Intervention: Full angioscopic preparation
Number of subjects: 0
Study 9579121 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation
Number of subjects: 0
Study 9579121 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioscopy and histology evaluation
Number of subjects: 0
Study 9579121 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvested vein in organ culture
Number of subjects: 0
Study 9579121 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioscopy
Number of subjects: 0
Study 7647691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.4 g n-3 fatty acids/day)
Number of subjects: 12
Study 7647691 — intervention group
Group type: COMPARATOR
Intervention: Corn oil supplements
Number of subjects: 12
Study 2699556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 27
Study 2699556 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 27
Study 799558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol alone
Number of subjects: 0
Study 799558 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine with oxprenolol
Number of subjects: 0
Study 799558 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg daily)
Number of subjects: 0
Study 799558 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine alone
Number of subjects: 0
Study 31441836 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA + Dexa (10 mg Dexa just after anesthesia and repeated at 24 hours post-surgery)
Number of subjects: 88
Study 31441836 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA + Dexa
Number of subjects: 88
Study 31441836 — intervention group
Group type: COMPARATOR
Intervention: TXA
Number of subjects: 88
Study 28384006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body intervention (3-day residential course + two 8-hour follow-up events)
Number of subjects: 30
Study 28384006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body intervention
Number of subjects: 30
Study 28384006 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 26055067 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FGF21 levels
Number of subjects: 9697
Study 26055067 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of FGF21 levels in a model of new on‐study total microvascular disease with established risk factors
Number of subjects: 9697
Study 23075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 35
Study 23075691 — intervention group
Group type: COMPARATOR
Intervention: PI/r
Number of subjects: 35
Study 21770241 — intervention group
Group type: EXPERIMENTAL
Intervention: Tang-shen-fang (TSF)
Number of subjects: 0
Study 21770241 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 19338427 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg
Number of subjects: 1132
Study 19338427 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg (third injection)
Number of subjects: 1132
Study 17375491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (details not provided)
Number of subjects: 0
Study 15515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injections of tropisetron
Number of subjects: 0
Study 15515413 — intervention group
Group type: COMPARATOR
Intervention: Topical application of local anaesthetics combined with depot corticosteroids
Number of subjects: 0
Study 15515413 — intervention group
Group type: COMPARATOR
Intervention: Local injection of prilocaine
Number of subjects: 0
Study 11718981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 30
Study 11718981 — intervention group
Group type: COMPARATOR
Intervention: Stress Reducing Strategies (SRS)
Number of subjects: 30
Study 11718981 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support interventions (both hypnosis and SRS)
Number of subjects: 30
Study 9399390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily
Number of subjects: 535
Study 9399390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg at night
Number of subjects: 535
Study 9399390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 8476803 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Doppler ultrasound
Number of subjects: 2025
Study 8476803 — intervention group
Group type: COMPARATOR
Intervention: Highly selective use of Doppler ultrasound
Number of subjects: 2025
Study 3624684 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized atropine (1.5 mg)
Number of subjects: 6
Study 3624684 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine (80 to 160 mg)
Number of subjects: 6
Study 3624684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin (50 mg three times daily for 10 doses)
Number of subjects: 6
Study 3624684 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized phosphate-buffered saline
Number of subjects: 6
Study 30999881 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month intervention including written materials, videos, peer support coaching, and group meetings focused on nutrition and physical activity.
Number of subjects: 0
Study 30999881 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month intervention materials focused on nutrition and physical activity best practices.
Number of subjects: 0
Study 30999881 — intervention group
Group type: COMPARATOR
Intervention: Comparison group receiving group meetings focused on reading readiness.
Number of subjects: 0
Study 30039161 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge telephone call within 4 days of discharge
Number of subjects: 966
Study 30039161 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge
Number of subjects: 966
Study 27849355 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cocoa flavanol (903 mg)
Number of subjects: 12
Study 27849355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 27849355 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 12
Study 27849355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Task (CT) post-exercise
Number of subjects: 12
Study 24859364 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL1 halving time <76 days (n = 74)
Number of subjects: 528
Study 24859364 — intervention group
Group type: COMPARATOR
Intervention: Imatinib treatment with BCR-ABL1 values not halving by 76 days (n = 21)
Number of subjects: 528
Study 22949275 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based interventions implemented by an interdisciplinary rehabilitation team
Number of subjects: 35
Study 22949275 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 patients discharged before implementation)
Number of subjects: 35
Study 20394488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality skin cream
Number of subjects: 4
Study 20394488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream vehicle
Number of subjects: 4
Study 20394488 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient oil
Number of subjects: 4
Study 20394488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cream emulsion
Number of subjects: 4
Study 20394488 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin (control)
Number of subjects: 4
Study 18028577 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free continuous psoas compartment block with 0.75% ropivacaine (0.4 mL kg(‐1) loading dose followed by 10 mL h(‐1) of 0.2% ropivacaine for 48 hours)
Number of subjects: 73
Study 18028577 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of 0.1% morphine and 0.12% ketorolac at 2 mL h(‐1) for 48 hours
Number of subjects: 73
Study 16210049 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (desloratadine 5 mg + montelukast 10 mg)
Number of subjects: 10
Study 16210049 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 10
Study 16210049 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 10
Study 16210049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12371974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized treatment after biopsy
Number of subjects: 96
Study 9925057 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF under fasting conditions
Number of subjects: 14
Study 9925057 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF with aluminum‐magnesium antacid
Number of subjects: 14
Study 9925057 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF with high‐fat meal
Number of subjects: 14
Study 7579503 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TAM) treatment
Number of subjects: 0
Study 7579503 — intervention group
Group type: COMPARATOR
Intervention: No systemic adjuvant therapy (Control)
Number of subjects: 0
Study 1703024 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mydriatic Polaroid retinal photography
Number of subjects: 2159
Study 1703024 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmoscopy with mydriasis
Number of subjects: 2159
Study 7208246 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement (Group 1): Subjects were shown a highly preferred slide following each correct detection.
Number of subjects: 24
Study 7208246 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results (Group 2): Subjects received a second, longer presentation of every item responded to and every critical one omitted.
Number of subjects: 24
Study 7208246 — intervention group
Group type: COMPARATOR
Intervention: Practice control (Group 3): Subjects faced a blank screen during inter-stimulus intervals.
Number of subjects: 24
Study 31005171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative breast MRI
Number of subjects: 210
Study 27072796 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment recommendation
Number of subjects: 100
Study 27072796 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment recommendation in psychiatric university hospital
Number of subjects: 100
Study 27072796 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment recommendation for patients with F2 diagnosis
Number of subjects: 100
Study 26363840 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 601
Study 26363840 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 601
Study 23290428 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol plus Isosorbide Mononitrate (IMN)
Number of subjects: 0
Study 23290428 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (control group)
Number of subjects: 0
Study 21453919 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol driven, nurse‐initiated discharge
Number of subjects: 131
Study 21453919 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 19583673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-physician co-managed programme
Number of subjects: 118
Study 19583673 — intervention group
Group type: COMPARATOR
Intervention: Routine conventional care (Control)
Number of subjects: 118
Study 17158523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antithrombotic therapy (antiplatelet plus moderate-level anticoagulant)
Number of subjects: 967
Study 17158523 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy alone
Number of subjects: 967
Study 15093869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild MR
Number of subjects: 2082
Study 15093869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe MR
Number of subjects: 2082
Study 15093869 — intervention group
Group type: COMPARATOR
Intervention: No MR
Number of subjects: 2082
Study 11707791 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia at T11 sensory level
Number of subjects: 8
Study 11707791 — intervention group
Group type: COMPARATOR
Intervention: Control without anesthesia
Number of subjects: 8
Study 8958162 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (1 g, two daily dosages)
Number of subjects: 30
Study 8958162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8958162 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (after crossover)
Number of subjects: 30
Study 8958162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after crossover)
Number of subjects: 30
Study 8023026 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0
Study 8023026 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 0
Study 3125029 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 51
Study 3125029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 3125029 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 51
Study 29033108 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 130
Study 29033108 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 130
Study 27650228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 196
Study 27650228 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsupplemented group)
Number of subjects: 196
Study 24783622 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.02 microg x kg(-1) x min(-1))
Number of subjects: 40
Study 24783622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23072285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived hydroxyapatite (BHA)
Number of subjects: 23
Study 23072285 — intervention group
Group type: COMPARATOR
Intervention: β-tricalcium phosphate (β-TCP)
Number of subjects: 23
Study 20138778 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily respiratory physiotherapy interventions until discharge
Number of subjects: 76
Study 20138778 — intervention group
Group type: COMPARATOR
Intervention: Standard medical/nursing care involving a clinical pathway
Number of subjects: 76
Study 18367284 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Number of subjects: 121
Study 18367284 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran bread
Number of subjects: 121
Study 18367284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread
Number of subjects: 121
Study 18367284 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 121
Study 15123946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection for pain relief
Number of subjects: 19
Study 15123946 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 19
Study 11159262 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 120
Study 11159262 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study 11398300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 703
Study 11398300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg
Number of subjects: 703
Study 11398300 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 703
Study 11398300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 7511501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index analysis of EEG during induction of anesthesia
Number of subjects: 39
Study 7511501 — intervention group
Group type: COMPARATOR
Intervention: Power spectral analysis of EEG
Number of subjects: 39
Study 3278497 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg i.v.
Number of subjects: 7
Study 3278497 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) i.v.
Number of subjects: 7
Study 29466249 — intervention group
Group type: EXPERIMENTAL
Intervention: TPP-related compounds (specifically bis-TPP, 2-butene-1,4-bis-TPP)
Number of subjects: 0
Study 29466249 — intervention group
Group type: EXPERIMENTAL
Intervention: TPP-related compounds (general)
Number of subjects: 0
Study 28803715 — intervention group
Group type: EXPERIMENTAL
Intervention: 20μg Hepatitis E Virus (HEV) p179 vaccine
Number of subjects: 120
Study 28803715 — intervention group
Group type: COMPARATOR
Intervention: 30μg HEV vaccine p239 Hecolin (control)
Number of subjects: 120
Study 28803715 — intervention group
Group type: EXPERIMENTAL
Intervention: 40μg Hepatitis E Virus (HEV) p179 vaccine
Number of subjects: 120
Study 25680558 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of trabectedin treatment after six cycles (27 patients)
Number of subjects: 178
Study 25680558 — intervention group
Group type: COMPARATOR
Intervention: Interruption of trabectedin treatment after six cycles (26 patients)
Number of subjects: 178
Study 25680558 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of trabectedin treatment (27 patients)
Number of subjects: 178
Study 25680558 — intervention group
Group type: COMPARATOR
Intervention: Interruption of trabectedin treatment (26 patients)
Number of subjects: 178
Study 23053269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 200 mg (single oral dose)
Number of subjects: 27
Study 22157480 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 38
Study 22157480 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 38
Study 18841294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin bolus
Number of subjects: 10
Study 18841294 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of Bivalirudin
Number of subjects: 10
Study 18841294 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 10
Study 18841294 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 10
Study 18841294 — intervention group
Group type: COMPARATOR
Intervention: UFH + eptifibatide
Number of subjects: 10
Study 18841294 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin + eptifibatide
Number of subjects: 10
Study 18841294 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin + eptifibatide
Number of subjects: 10
Study 16817264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with needle-retaining time of 20 minutes
Number of subjects: 251
Study 16817264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with needle-retaining time of 40 minutes
Number of subjects: 251
Study 16817264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with needle-retaining time of 60 minutes
Number of subjects: 251
Study 12500072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128
Study 12500072 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded rater's guess of treatment assignment
Number of subjects: 128
Study 12500072 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 128
Study 10623703 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel at a dose of 100 mg/m(2) intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days
Number of subjects: 80